Coralville's VIDA Diagnostics Partners with Firm on System Development

ICAD client develops quantitative imaging software for the advanced analysis of pulmonary diseases

VIDA Diagnostics and Veran Medical Technologies, which develops minimally invasive delivery of interventional oncology therapies, announced the companies have signed a definitive agreement covering joint development and distribution of an endobronchial lung navigation and biopsy system.

"The promise of this partnership is a more accurate and cost-effective procedure to evaluate the indeterminate lung nodule," said Susan Wood, president and CEO of VIDA Diagnostics, in a press release. "VIDA's PW2 is a highly validated quantitative pulmonary analysis solution with over 25,000 CT exams processed. Combining our quantitative roadmap and clinical expertise with Veran's industry leading navigation and registration tracking technology, results in an elegant, exact guidance planning solution with instant registration and breathing compensation."

Lung cancer remains the No. 1 cause of cancer death in the United States. While most solitary lung nodules are benign, they may represent an early stage of lung cancer. As a result, the early diagnosis and management of lung nodules is critical to improve patient survival.